Loading...
XJPX
4587
Market cap809mUSD
Jul 10, Last price  
1,019.00JPY
1D
-0.34%
1Q
-15.85%
Jan 2017
-66.48%
IPO
-11.39%
Name

PeptiDream Inc

Chart & Performance

D1W1MN
XJPX:4587 chart
P/E
—
P/S
7.07
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-0.08%
Rev. gr., 5y
9.66%
Revenues
18.52b
-60.32%
91,135,000601,549,000269,004,000678,269,000818,901,0002,474,499,0004,327,878,0004,895,747,0006,426,891,0007,216,622,0002,074,674,00011,677,253,0009,422,214,00026,852,430,00028,712,194,00046,676,523,00018,521,234,000
Net income
-3.75b
L
-18,968,000176,128,0009,971,000137,180,000148,512,0001,004,164,0001,581,288,0001,890,750,0002,335,216,0002,770,141,000-976,928,0004,448,357,0002,573,232,0007,554,358,0003,035,832,00015,014,922,000-3,749,204,000
CFO
-13.28b
L
425,624,000-150,484,000234,566,00072,174,0001,386,143,0001,533,057,0001,530,776,0001,022,716,0004,480,938,000241,982,0001,732,733,0006,654,708,000-295,729,00012,382,969,00023,844,988,000-13,276,876,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

PeptiDream Inc. functions as a biopharmaceutical enterprise, concentrating on the identification and progression of therapeutic compounds such as constrained peptides, small molecules, and peptide-drug conjugates. The company's unique product pipeline is underpinned by its proprietary Peptide Discovery Platform System (PDPS), an advanced technology specifically designed for the development of peptide-based drugs. Additionally, PeptiDream maintains an exclusive licensing and collaborative research partnership with Takeda Pharmaceutical Company Limited, aimed at creating peptide drug conjugates for the treatment of neuromuscular conditions. Established in 2006, the company's primary offices are situated in Kawasaki, Japan.
URL
https://www.peptidream.com/
IPO date
Jun 11, 2013
Employees
692
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122019‑062018‑062017‑06
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT